Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SADEL

Financiado

Cerrado

Scaffolds for alternative delivery

The SME-based SADEL consortium intends to develop the first generation of oral bio-therapeutics tackling disease targets in the digestive tract, by making optimal use of the Nanofitin (Nf) protein scaffold. Nf based drugs will pro... ver más

31/12/2016

INNOVHUB STAZIONI...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

INNOVHUB STAZIONI SPERIMENTALI PER LINDUSTRI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-12-31 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

INNOVHUB STAZIONI SPERIMENT...

0.00€ | Lider

AFFILOGIC

N.D. | Participante

BIOMEDICALSCIENCES RESEARCH...

N.D. | Participante

IBET

N.D. | Participante

Proyectos interesantes

NEW DEAL

Medical Technol...

Nanotechnology

6M€ Cerrado

TRANS-INT

Medical Technol...

Nanotechnology

11M€ Cerrado

GENEGUT

Medical Technol...

Nanotechnology

5M€ Cerrado

EUIN2013-51211

Nanotechnology

Medical Technol...

23K€ Cerrado

GENEGUT

Medical Technol...

Nanotechnology

5M€ Cerrado

BES-2015-071304

Medical Technol...

Nanotechnology

93K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

INNOVHUB STAZIONI SPERIMENTALI PER LINDUSTRI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The SME-based SADEL consortium intends to develop the first generation of oral bio-therapeutics tackling disease targets in the digestive tract, by making optimal use of the Nanofitin (Nf) protein scaffold. Nf based drugs will progress through routes not travelled by antibodies while interacting with targets not modulated by chemical compounds. Existing Nf hits against validated targets will progress to the preparation of Phase I Clinical trials in Ulcerative Colitis (UC). To achieve this, SADEL assembles a virtual biopharmaceutical company with SMEs (70%), academics, clinicians and pharma industry with all cutting-edge skills: production (including GMP), analytics, formulation, preclinical and clinical development, up to licensing. Nfs are small (optimal tissue penetration), exhibit strong resistance to pH and human intestinal fluids (long half-life in digestive track) and their high affinity implies low effective concentration. They also demonstrate strong potential for optimizing pharmacological properties, including reducing immunogenicity. The Nf based drugs will be administered orally, reducing the systemic exposure and avoiding the safety issues reported with systemic administration of antibodies. This requires large quantities of proteins for frequent administration. Nfs are produced in bacterial systems for which GMP-compliant processes are broadly adopted in the industry, with a low cost of goods. The resulting proteins will be formulated for optimal release at the sites of action. The project is designed to address unmet technical challenges while avoiding external risks beyond those related to the scaffold behaviour itself. All additional elements are chosen for documented validation, from targets to evaluation protocols. Achieving SADEL aims will solve unmet patient needs by providing affordable, safe, efficient products in a format raising comfort and compliance to treatment. It will also assess the therapeutic potential of the Nanofitin platform.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores